Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer
Study Details
Study Description
Brief Summary
This study will test if the use of DysportTM (abobotulinumtoxinA) improves wound healing and scarring after Mohs surgery. Research in the laboratory as well as previous studies in humans have shown improved wound healing and scarring with the use of a similar medication called Botox.
Dysport may improve wound healing and scarring by relaxing facial muscles and therefore minimizes the muscle tension and possibly the inflammation around the wound.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Primary Objective:
-To evaluate the efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Visual Analogue Scale (VAS) at 6 weeks post surgery.
Secondary Objectives:
-
To evaluate efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Patient and Observer Assessment Scale (POSAS) at week 1, 6, and 24.
-
To evaluate the efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Visual Analogue Scale (VAS) at week 1 and 24 post surgery.
-
To evaluate patient satisfaction
-
To evaluate safety (adverse events)
This is a 6 month, prospective, multicenter, double-blinded, randomized, placebo-controlled study. A total of 40 male or female healthy volunteers, 20 in each arm, will be enrolled. Up to 10 more patients can be enrolled to account for patient drop-out. Subjects will all undergo Mohs micrographic surgical removal of a skin cancer lesion on the forehead followed by reconstruction. Subjects will be randomized to receive either aboBTX-A injection or placebo injection in the frontalis, procerus, and corrugator muscles prior to reconstruction. Photographs, POSAS, and clinical assessments will be taken immediately after initial wound closure, at 1 week follow-up, at 6 weeks follow-up, and at 6 months follow-up. Adverse events will also be reviewed at each study visit. After the completion of the study, the photographs will be assessed (blinded as to the patient identifiers) using a 10 cm visual analog scale (VAS). The first few photographs will be evaluated by the surgeons together to calibrate the VAS and ensure inter-reliability.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dysport (abobotulinumtoxinA) Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry. |
Drug: Dysport (abobotulinumtoxinA)
Intramuscular injection effects lasting up to 3 months
Other Names:
|
| Placebo Comparator: Placebo
|
Drug: Bacteriostatic 0.9% Sodium Chloride (vehicle)
Intramuscular injection
|
Outcome Measures
Primary Outcome Measures
- Visual Analogue Scale (VAS) [6 weeks post surgery]
It consists of a 10 point scale to assess global scar assessment. Scar photographic images are assessed by independent physicians, and previous studies have shown very high intrarater consistency.
Secondary Outcome Measures
- Patient and Observer Assessment Scale (POSAS) [at week 1, 6, and 24 post surgery]
The Patient and Observer Scar Assessment Scale (POSAS) consists of two numeric scales. One scale is completed by the patients, the other by the clinician. This scale is different than previous scales because it takes the patient's input into consideration. It has good internal consistency and interobserver reliability. The assessment will take place at Day 0, Week 1, Week 6, and Month 6.
- Visual Analogue Scale (VAS) [at week 1 and 24 post surgery]
Evaluate efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Visual Analogue Scale (VAS)
Eligibility Criteria
Criteria
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for enrollment:
-
Ability to understand the risks, benefits, and alternative to participation and give informed consent
-
Have biopsy proven skin cancer on the medial forehead that is amenable to Mohs surgery. Medial forehead is defined as the area superiorly from the hairline, inferiorly at the eyebrow, and laterally to the tip of the lateral brow (see diagram).
-
Undergoing elective reconstruction of biopsy proven skin cancer that is amenable to Mohs surgery with defect size measuring 1.0 cm or greater
-
If female, not currently pregnant, no potential for pregnancy, or if of child-bearing age, must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for 30 days after the last dose of study drug. A negative urine pregnancy test is required at study entry for female subjects of childbearing potential: a woman is considered to be of child bearing potential unless she has had a tubal ligation, total hysterectomy, bilateral oopherectomy, or is postmenopausal (without a menstrual period for at least one year)
-
Agrees to not use disallowed concomitant medications (retinoids)
Exclusion Criteria:
The presence of any of the following will exclude a patient from study enrollment.
-
Pregnant women, women who are breastfeeding, or women of child bearing age who are unwilling to use adequate contraception (described above) during the study period
-
Current or past history of a neuromuscular disease (such as myasthenia gravis, amyotrophic lateral sclerosis, Eaton-Lambert syndrome)
-
Currently taking aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents)
-
History of radiation therapy or chemotherapy
-
History of keloid or other hypertrophic scar formation
-
Current or past history of scleroderma
-
Has used botulinum toxin in the forehead area within one year.
-
Has significant resting eyebrow ptosis
-
Has used any topical retinoids to the forehead area within the past 4 weeks
-
Undergo any scar revision procedure for the duration of the study including intralesional kenalog, laser treatment, and/or scar revision surgeries
-
Any hypersensitivity to any component of abobotulinumtoxinA (i.e. cow milk protein) or any previous hypersensitivity to any botulinum toxin A or related product.
-
Non-English speaking: These patients are excluded since translation of the informed consent into other languages is time-consuming and expensive as it requires a bona fide translator for the particular language of interest and this type of person may be difficult to locate.
-
House staff and students, medical students on a clerkship, and employees related to study personnel or who work for any study personnel, and members of the study team are not eligible to participate in this study as a subject.
-
The investigator feels that for any reason the subject is not eligible to participate in the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center | Cleveland | Ohio | United States | 44106 |
| 2 | UH Cleveland Medical Center-Westlake | Westlake | Ohio | United States | 44145 |
Sponsors and Collaborators
- University Hospitals Cleveland Medical Center
Investigators
- Principal Investigator: Margaret Mann, MD, University Hospitals Cleveland Medical Center
Study Documents (Full-Text)
More Information
Publications
None provided.- CASE1Z12
Study Results
Participant Flow
| Recruitment Details | Study was terminated, only 9 participants were actually enrolled. |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Dysport (abobotulinumtoxinA) | Placebo |
|---|---|---|
| Arm/Group Description | Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry. Dysport (abobotulinumtoxinA): Intramuscular injection effects lasting up to 3 months | Bacteriostatic 0.9% Sodium Chloride (vehicle): Intramuscular injection |
| Period Title: Overall Study | ||
| STARTED | 5 | 4 |
| COMPLETED | 0 | 0 |
| NOT COMPLETED | 5 | 4 |
Baseline Characteristics
| Arm/Group Title | Dysport (abobotulinumtoxinA) | Placebo | Total |
|---|---|---|---|
| Arm/Group Description | Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry. Dysport (abobotulinumtoxinA): Intramuscular injection effects lasting up to 3 months | Bacteriostatic 0.9% Sodium Chloride (vehicle): Intramuscular injection | Total of all reporting groups |
| Overall Participants | 5 | 4 | 9 |
| Age (Count of Participants) | |||
| <=18 years |
0
0%
|
0
0%
|
0
0%
|
| Between 18 and 65 years |
2
40%
|
3
75%
|
5
55.6%
|
| >=65 years |
3
60%
|
1
25%
|
4
44.4%
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
3
60%
|
4
100%
|
7
77.8%
|
| Male |
2
40%
|
0
0%
|
2
22.2%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |||
| Hispanic or Latino |
0
0%
|
0
0%
|
0
0%
|
| Not Hispanic or Latino |
5
100%
|
4
100%
|
9
100%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
| Race (NIH/OMB) (Count of Participants) | |||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
| Asian |
0
0%
|
0
0%
|
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
0
0%
|
0
0%
|
0
0%
|
| White |
5
100%
|
4
100%
|
9
100%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
Outcome Measures
| Title | Visual Analogue Scale (VAS) |
|---|---|
| Description | It consists of a 10 point scale to assess global scar assessment. Scar photographic images are assessed by independent physicians, and previous studies have shown very high intrarater consistency. |
| Time Frame | 6 weeks post surgery |
Outcome Measure Data
| Analysis Population Description |
|---|
| Not collected |
| Arm/Group Title | Dysport (abobotulinumtoxinA) | Placebo |
|---|---|---|
| Arm/Group Description | Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry. Dysport (abobotulinumtoxinA): Intramuscular injection effects lasting up to 3 months | Bacteriostatic 0.9% Sodium Chloride (vehicle): Intramuscular injection |
| Measure Participants | 0 | 0 |
| Title | Patient and Observer Assessment Scale (POSAS) |
|---|---|
| Description | The Patient and Observer Scar Assessment Scale (POSAS) consists of two numeric scales. One scale is completed by the patients, the other by the clinician. This scale is different than previous scales because it takes the patient's input into consideration. It has good internal consistency and interobserver reliability. The assessment will take place at Day 0, Week 1, Week 6, and Month 6. |
| Time Frame | at week 1, 6, and 24 post surgery |
Outcome Measure Data
| Analysis Population Description |
|---|
| Not collected |
| Arm/Group Title | Dysport (abobotulinumtoxinA) | Placebo |
|---|---|---|
| Arm/Group Description | Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry. Dysport (abobotulinumtoxinA): Intramuscular injection effects lasting up to 3 months | Bacteriostatic 0.9% Sodium Chloride (vehicle): Intramuscular injection |
| Measure Participants | 0 | 0 |
| Title | Visual Analogue Scale (VAS) |
|---|---|
| Description | Evaluate efficacy of using aboBTX-A to improve wound healing prior to Mohs micrographic surgery and reconstruction for skin cancer as measured by the Visual Analogue Scale (VAS) |
| Time Frame | at week 1 and 24 post surgery |
Outcome Measure Data
| Analysis Population Description |
|---|
| Not collected |
| Arm/Group Title | Dysport (abobotulinumtoxinA) | Placebo |
|---|---|---|
| Arm/Group Description | Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry. Dysport (abobotulinumtoxinA): Intramuscular injection effects lasting up to 3 months | Bacteriostatic 0.9% Sodium Chloride (vehicle): Intramuscular injection |
| Measure Participants | 0 | 0 |
Adverse Events
| Time Frame | 7 Months | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Dysport (abobotulinumtoxinA) | Placebo | ||
| Arm/Group Description | Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry. Dysport (abobotulinumtoxinA): Intramuscular injection effects lasting up to 3 months | Bacteriostatic 0.9% Sodium Chloride (vehicle): Intramuscular injection | ||
All Cause Mortality |
||||
| Dysport (abobotulinumtoxinA) | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/5 (0%) | 0/4 (0%) | ||
Serious Adverse Events |
||||
| Dysport (abobotulinumtoxinA) | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/5 (0%) | 0/4 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Dysport (abobotulinumtoxinA) | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/5 (0%) | 0/4 (0%) | ||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
| Name/Title | Dr. Kevin Cooper |
|---|---|
| Organization | University Hospitals Cleveland Medical Center |
| Phone | 216-844-3100 |
| Kevin.Cooper@UHhospitals.org |
- CASE1Z12